1. Scrip
  2. >>Business
  3. >>Deals

Syros Gets ‘Tyme’ To Bring Lead Candidate To Pivotal Readout

 
• By Joseph Haas

Gene-expression focused Syros adds about $190m to its coffers with Tyme merger and PIPE financing. This will get it past pivotal data for tamibarotene and enable Phase III development of a leukemia candidate.

Sand running through the bulbs of an hourglass measuring the passing time in a countdown to a deadline, on a dark background with copy space.
Time was a primary obstacle for Syros, until it agreed to merge with Tyme

Syros Pharmaceuticals, Inc. significantly extended its financial runway through three concurrent transactions on 5 July that are expected to fund company operations into 2025 and get it well past the expected readout of pivotal Phase III data for its lead candidate tamibarotene in higher-risk myelodysplastic syndrome (HR-MDS) patients. In the process, Syros will merge with Tyme Technologies, Inc., acquiring about $60m in cash and that company’s stalled cancer metabolism-based therapy SM-88.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business